Navigation Links
Men Treated for Localized Prostate Cancer Could Benefit From Pomegranate Juice Consumption
Date:4/27/2009

LINTHICUM, Md., April 27 /PRNewswire-USNewswire/ -- Pomegranate juice may slow the progression of post-treatment prostate cancer recurrence, according to new long-term research results being presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA). Researchers found that men who have undergone treatment for localized prostate cancer could benefit from drinking pomegranate juice.

The two-stage clinical trial followed a total of 48 participants over six years. Eligible participants had a rising PSA after surgery or radiotherapy, a PSA greater than 0.2 ng/ml and less than 5 ng/ml and a Gleason score of 7 or less. These patients were treated by drinking eight ounces of pomegranate juice daily. Currently, in the sixth year of treatment, active patients who remain on the study have a median total follow-up of 56 months. These participants continue to experience a significant increase in PSA doubling time following treatment, from a mean of 15.4 months at baseline to 60 months post-treatment, with a median PSA slope decrease of 60 percent, 0.06 to 0.024.

Researchers compared active patients, who remain on the study, with non-active patients, who no longer remain on the study. Though these two groups demonstrated similar mean PSA doubling times at baseline, both the PSA doubling time prolongation and the decline in median PSA slope were greater in active patients when compared to non-active patients.

"This study suggests that pomegranate juice may effectively slow the progression of prostate cancer after unsuccessful treatment," said Christopher Amling, MD, an AUA spokesman. "This finding and other ongoing research might one day reveal that pomegranate juice is an effective prostate cancer preventative agent as well."

Parts of this ongoing study suggest that some patients may be more sensitive to the effects of pomegranate juice on PSA doubling time. Phase three of this study is currently underway to further evaluate the benefits of pomegranate juice in a placebo-controlled manner.

NOTE TO REPORTERS: Experts are available to discuss these studies outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications Office at the number below or e-mail Lacey Dean at LDean@AUAnet.org.

Pantuck, A; Zomorodian, N; Rettig, M; Aronson, W; Heber, D; Belldegrun, A. Long term follow up of phase 2 study of pomegranate juice for men with prostate cancer shows durable prolongation of PSA doubling time. J Urol, suppl. 2009: 181, 4, abstract 826.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 16,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.

    MEDIA CONTACTS:  AUA Media Relations (on-site):  312-528-8253
    Wendy Isett (cell):  410-977-4770


'/>"/>
SOURCE American Urological Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. First Swiss Patients Treated with the Percutaneous MitraClip(R) System
2. New Proton Therapy Equipment Enables More Tumors to be Treated
3. New Research Suggests Platelet Stickiness May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease
4. Cardiac Disease in Women Remains Untreated for Decades
5. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
6. Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
7. Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
8. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
9. SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
10. American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for Depression
11. First European Patients Treated With the Percutaneous MitraClip(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 Persistence Market ... global market for intraoperative imaging, excerpts from which ... US$ 513.9 million. According to the report, the ... the grounds of increasing adoption of minimally-invasive surgeries ... diagnostic imaging for neurosurgeries. The world,s leading medical ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Cardiac Prosthetic ... 9.2% over the next decade to reach approximately $8.9 billion by ... forecasts for all the given segments on global as well as ...
(Date:2/23/2017)... 2017 MabVax Therapeutics Holdings, Inc ... company, announces that it has received notice from ... the initiation a Phase I clinical trial with ... MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel ... initiate the phase I clinical trial in patients ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for standing designer ... stand solutions representative to the Minneapolis Home and Garden Show which is being held ... is garnering national attention is the Minneapolis Convention Center. , From its broad ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came time to ... in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand opening presented ... $51 million to purchase and renovate the 185,000 square-foot office complex, which was ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy ... The technology is so cutting edge, in fact, the U.S. Food and Drug ... procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... certification exam and eligibility requirements effective with the April 2017 testing period. NACCM, ... , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ensure ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... analytics to accurately understand each Medicare Advantage member’s risk, identify any gaps-in-coding, ... This new solution helps transform the HCC Risk Adjustment process from a ...
Breaking Medicine News(10 mins):